What Advanced Biologics does

Advanced Biologics operates as Isto Biologics, a privately held, pure-play orthobiologics company headquartered in Hopkinton, Massachusetts, organized through five wholly-owned subsidiaries (Arteriocyte Medical Systems, Isto Technologies II, Progenicare, Progenicare Therapeutics, and Advanced Transfusion Services). The company was founded in 2009 and operates with a headcount in the 11–50 range. Its portfolio spans three product categories: Autologous Therapies (the market-leading Magellan concentration system for PRP, concentrated bone marrow aspirate, and platelet-poor plasma, plus the Precise system and Lightning Needle), Allografts (the Influx family including Fibrant, ProteiOS, SPARC, PLUS, Sponge, and OsseoGEN), and Synthetics (InQu biosynthetic bone graft with demonstrated clinical superiority over iliac crest bone graft).

The company's core technology is centered on point-of-care biologics preparation and tissue processing rather than software or AI. Revenue is generated through one-time product sales of medical devices and biologic tissue products to healthcare providers, with pricing handled via quote requests and direct representative engagement rather than disclosed list pricing. Distribution combines enterprise field sales with regional representatives and a medical distributor network, enabling both direct hospital/surgical center relationships and broader channel-based reach. The company markets primarily to orthopedic and spine surgeons, with secondary segments including medical distributors, hospital value analysis committees, and clinical researchers.

The company maintains an active digital presence through LinkedIn and YouTube and captures leads through HubSpot-powered quote and representative contact forms. No funding rounds, revenue figures, M&A transactions, or regulatory actions are disclosed in the available data, and no AI/ML capabilities, API infrastructure, or software products are described. Operational signals — global customer footprint, continuous product line expansion, and an integrated multi-subsidiary structure — suggest an established but privately opaque operating business.

Name

Advanced Biologics

Legal name

Isto Biologics

Website

https://advancedbiologics.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Isto Biologics (Advanced Biologics) is a privately held, pure-play orthobiologics company developing autologous concentration systems, allograft tissue products, and biosynthetic bone grafts for orthopedic and spine surgeons globally, distributed via direct field sales and medical distributors.

Ownership category

akta.pro rank

Product category

Orthobiologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industries

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Spine (Orthopedic Spine) (HLAKALAE), Orthopedic Surgery (Operative Orthopedics) (HLAKALAC)

Keywords

• Orthobiologic solutions
• Autologous concentration systems
• Allograft bone grafts
• Biosynthetic bone grafts
• Regenerative medicine products

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Medical Device and Biologics Product Sales: Isto Biologics generates revenue through the sale of its portfolio of orthobiologic products including autologous concentration systems, allograft tissue products, and synthetic bone graft substitutes to healthcare providers, hospitals, and surgical centers.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Advanced Biologics (operating as Isto Biologics) develops and sells orthobiologic medical products across three categories: Autologous Therapies (including the Magellan Autologous Concentration System, Precise PRP system, and Lightning Needle for PRP and bone marrow aspirate preparation), Allografts (the Influx product family including ProteiOS, Fibrant, SPARC, PLUS, Sponge, and OsseoGEN derived from donor tissue), and Synthetics (the InQu cell-friendly biosynthetic bone graft). The portfolio is sold to surgeons, hospitals, and surgical centers for orthopedic and spinal procedures requiring bone and tissue healing solutions.

Product overview

Isto Biologics (Advanced Biologics) is a 100% biologics-focused company offering three main product categories: Autologous Therapies, Allografts, and Synthetics. The Autologous Therapies portfolio includes the Magellan Autologous Concentration System (market-leading device for creating PRP, cBMA, and Platelet Poor Plasma), Precise (for Leukocyte Rich/Leukocyte Poor PRP), and Lightning Needle. The Allografts portfolio centers on the Influx family of products derived from donor tissue, including ProteiOS (protein blend), Fibrant (cortical fiber), SPARC (next generation), PLUS, Sponge, and OsseoGEN. The Synthetics portfolio includes InQu, a cell-friendly biosynthetic bone graft with proven clinical efficacy. The company operates through subsidiaries including Arteriocyte Medical Systems, Inc., Isto Technologies II, LLC, Progenicare, LLC, Progenicare Therapeutics, LLC, and Advanced Transfusion Services, LLC.

Differentiator

Problem solved

Functional benefit

Brands

• Magellan: Leading autologous concentration system for creating autologous therapies including Platelet Rich Plasma, Concentrated Bone Marrow Aspirate, and Platelet Poor Plasma
• Precise
• Lightning Needle
• Influx
• Influx Fibrant
• Influx ProteiOS
• Influx SPARC
• Influx PLUS
• Influx Sponge
• OsseoGEN
• InQu

Products and services

• Magellan Autologous Concentration System Market-leading autologous concentration device used to create autologous therapies including Platelet Rich Plasma (PRP), Concentrated Bone Marrow Aspirate (cBMA), and Platelet Poor Plasma (PPP). Sold to surgeons, physicians, hospitals, and surgical centers for use in orthopedic and spine procedures.
• Precise PRP System Newest addition to the Autologous Therapies line providing precision targeting options to create Leukocyte Rich and Leukocyte Poor PRP. Used by surgeons and physicians performing autologous procedures.
• Lightning Needle Needle technology for autologous therapy procedures including bone marrow aspiration. Sold to surgeons and physicians performing autologous cell-based procedures.
• Influx Allograft Product Line Advanced allograft product line derived from donor tissue, setting the standard for bone grafting solutions. Used by surgeons and hospitals for bone grafting and spinal fusion procedures.
• Influx Fibrant Breakthrough cortical fiber allograft offering enhanced structural properties for bone grafting procedures. Used by surgeons performing bone grafting and fusion surgeries.
• Influx ProteiOS Blend of allograft-derived proteins for bone grafting applications. Used by surgeons and physicians for orthopedic bone repair procedures.
• Influx SPARC Next generation allograft offering advanced properties for surgical bone repair and fusion procedures. Sold to surgeons and hospitals performing spinal and orthopedic fusion.
• Influx PLUS Enhanced allograft product within the Influx family offering additional capabilities for bone grafting procedures. Used by surgeons for bone repair and fusion surgeries.
• Influx Sponge Sponge-form allograft product designed for specific surgical applications requiring conformable grafting material. Sold to surgeons for bone grafting applications.
• OsseoGEN Allograft product in the Influx family for bone generation applications. Used by surgeons and physicians for orthopedic bone repair procedures.
• InQu Biosynthetic Bone Graft Cell-friendly biosynthetic bone graft with proven clinical efficacy leading to faster bone fusion while outperforming the fusion rates of ICBG (Iliac Crest Bone Graft). Sold to surgeons, hospitals, and surgical centers for bone grafting and fusion procedures.

Quantifiable outcome

• InQu biosynthetic bone graft leads to faster bone fusion while outperforming fusion rates of ICBG (Ilium Crest Bone Graft)

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bioventus: Pure-play orthobiologics company offering bone graft substitutes (including SIGNAFUSE) and joint preservation therapies. Closely comparable business model to Isto as a focused orthobiologics specialist serving surgeons and hospitals.
• Wright Medical (Stryker Trauma & Extremities): Orthopedic biologics franchise now part of Stryker, with allograft and synthetic bone graft offerings (e.g., AUGMENT). Direct competitor to Isto's allograft and synthetic bone graft portfolio in extremities and orthopedic reconstruction.
• NuVasive / Globus Medical: Spine-focused medtech with orthobiologic offerings (e.g., AttraX, Osteocel) used in spinal fusion procedures. Highly comparable to Isto's spine-focused bone graft substitute and allograft portfolio.
• Arthrex: Orthopedic medtech specializing in sports medicine and autologous biologic therapies, including PRP and bone marrow concentration systems. Directly comparable to Isto's Magellan autologous concentration franchise and surgical needle offerings.

Broad incumbents

• Integra LifeSciences: Diversified medical device company with orthobiologic and regenerative tissue products used in spine, orthopedic, and neurosurgical procedures. Overlaps with Isto's allograft and regenerative medicine portfolio.
• Medtronic: Diversified medtech major with Infuse Bone Graft / rhBMP-2 — one of the most established orthobiologic and bone graft substitute franchises. Competes directly with Isto's Influx and InQu lines in spinal fusion, and far larger sales coverage to hospitals.
• Zimmer Biomet: Major orthopedic medtech with a biologics portfolio including bone graft substitutes and regenerative solutions used in joint reconstruction and spine. Competes with Isto across autologous, allograft, and synthetic categories at scale.
• DePuy Synthes (Johnson & Johnson): Orthopedic and spine medtech division of J&J with a broad biologics portfolio including allograft and synthetic bone graft products. Competes with Isto's allograft and synthetic categories with deep hospital enterprise coverage.
• Stryker: Large orthopedic and spine medtech with biologic and bone graft substitute offerings (including through its Wright Medical acquisition). Competes with Isto across allograft and synthetic bone graft categories with substantially larger sales and R&D scale.

Emerging players

• Bone Biologics: Emerging orthobiologics company developing bone graft substitutes for spinal fusion. Comparable in focus area (bone graft substitutes for spine) but smaller and earlier-stage than Isto, with narrower commercial reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCtu3EDFsT5_GdwOj8iOFg1g
• LinkedInlinkedin.com/company/isto-biologics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advanced Biologics